Boron Biologicals Inc. (BBI) announced that it has signed aresearch contract and licensing agreement with the Frenchpharmaceutical company Guerbet S.A.
BBI of Raleigh, N.C., will design, synthesize and characterizenew contrast media for use in X-ray imaging, while Guerbetwill provide animal testing and selection for the newcompounds. The partners will jointly own any patents resultingfrom the collaborative effort. As well, Guerbet will receiveexclusive marketing and distribution rights to thesecompounds.
(c) 1997 American Health Consultants. All rights reserved.